NCT00525161View on ClinicalTrials.gov

Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2015

Conditions
Breast Cancer
Interventions
DRUG

sorafenib

400 mg PO (orally) twice daily for 12 months from study enrollment or until disease progression, whichever occurs first.

Trial Locations (1)

40536

University of Kentucky, Lexington

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Suleiman Massarweh

OTHER

NCT00525161 - Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer | Biotech Hunter | Biotech Hunter